These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26813500)

  • 1. [Pathogenesis and clinical condition of hyperphosphatemic diseases].
    Hamano N; Fukagawa M
    Clin Calcium; 2016 Feb; 26(2):207-13. PubMed ID: 26813500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
    Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
    Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphate-a poison for humans?
    Komaba H; Fukagawa M
    Kidney Int; 2016 Oct; 90(4):753-63. PubMed ID: 27282935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Strategies aiming to control hyperphosphatemia in chronic kidney disease].
    Ureña Torres PA
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S95-S101. PubMed ID: 28577750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary management of phosphorus retention in chronic kidney disease: a review.
    Amiri FS
    Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
    Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
    Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the gastrointestinal tract in phosphate homeostasis in health and chronic kidney disease.
    Marks J; Debnam ES; Unwin RJ
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):481-7. PubMed ID: 23666413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism.
    Kuro-o M
    Nat Rev Nephrol; 2013 Nov; 9(11):650-60. PubMed ID: 23774819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphate homeostasis and disorders.
    Manghat P; Sodi R; Swaminathan R
    Ann Clin Biochem; 2014 Nov; 51(Pt 6):631-56. PubMed ID: 24585932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphate: a stealthier killer than previously thought?
    Gonzalez-Parra E; Tuñón J; Egido J; Ortiz A
    Cardiovasc Pathol; 2012; 21(5):372-81. PubMed ID: 22425627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental advances in mineral metabolism].
    Valdivieso JM
    Nefrologia; 2008; 28 Suppl 5():47-50. PubMed ID: 18847420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Many faces of phosphate].
    Fukumoto S
    Clin Calcium; 2016 Feb; 26(2):185. PubMed ID: 26995812
    [No Abstract]   [Full Text] [Related]  

  • 14. [The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease].
    Mukhin NA; Milovanov YS; Kozlovskaya LV; Dobrosmyslov IA; Milovanova LY
    Ter Arkh; 2016; 88(4):41-45. PubMed ID: 27070162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications.
    Yee J; Rosenbaum D; Jacobs JW; Sprague SM
    Am J Nephrol; 2021; 52(7):522-530. PubMed ID: 34515051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphate intake, hyperphosphatemia, and kidney function.
    Rubio-Aliaga I; Krapf R
    Pflugers Arch; 2022 Aug; 474(8):935-947. PubMed ID: 35511366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
    Folsom LJ; Imel EA
    Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Disorders of phosphate metabolism].
    Fukumoto S
    Rinsho Byori; 2010 Mar; 58(3):225-31. PubMed ID: 20408440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder.
    Tsuboi Y; Ohtomo S; Ichida Y; Hagita H; Ozawa K; Iida M; Nagao S; Ikegami H; Takahashi T; Horiba N
    Kidney Int; 2020 Aug; 98(2):343-354. PubMed ID: 32624180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations.
    Cozzolino M; Ketteler M; Wagner CA
    Expert Opin Ther Targets; 2020 May; 24(5):477-488. PubMed ID: 32191548
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.